


ORDERING PHYSICIAN: Physician Name, MD		
RECEIVING HEALTHCARE PROVIDER Clinic United Partnership Example of Oklahoma University 1234 Pennsylvania Ave, Bldg 100, Ste 123, Dept of Rheumatology Anytown, OK 12345 Phone: 555-555-1234 / Fax: 555-555-1234	SPECIMEN Collection Date: JUL-24-2020 Receipt Date: JUL-25-2020	PATIENT Name: Jane Doe Date of Birth: NOV-1-1970 Patient ID: 000-000-0000 Gender: Female TRF ID: 00000000-00
	REPORT Report Date: JUL-30-2020	

Vectra Molecular Result

Vectra Score	Risk of RP	Change in Score	Vectra Score Interpretation
72 HIGH (45-100)	20% 1-Year Risk of Radiographic Progression	 Meaningful Increase ≥ 8 Units	■ High Vectra Score: 72 Patient has a High Vectra Score that increased by 8 or more units from the previous score, which was also in the High category. Patient is at increased risk for radiographic progression. Consider adjusting treatment regimen to reduce inflammation, and retesting at the next clinical visit.

VECTRA SCORE DESCRIPTION


Vectra Disease Activity Levels: ■ Low: 1 to 29 ■ Moderate: 30 to 44 ■ High: 45 to 100

Vectra Score measures the concentrations of 12 serum proteins. An algorithm is applied to these concentrations to calculate a disease activity score on a scale of 1 to 100. The Vectra Score is personalized based on the age, gender, and adiposity of the patient.

RISK OF RADIOGRAPHIC PROGRESSION (RP)

The risk of RP is shown as a function of Vectra Score (see graph, right). The definition of RP is a 1-year total Sharp score change of >5 units. Increased risk of RP means a greater chance of irreversible joint damage.


Patient serostatus may affect the risk of radiographic progression. Thus, the actual risk of radiographic progression may be higher if this patient is seropositive and lower if this patient is seronegative.



CHANGE IN SCORE DESCRIPTION

Change in Score is assessed in relation to the Minimally Important Difference (MID) for Vectra. The MID for patients with a Moderate or High Vectra Score is 8.0.

VECTRA SCORES OVER TIME Complete score history shown on last page.



*As of December 4, 2017 the Vectra Score is adjusted based on the age, gender and adiposity of the patient.

While the Vectra Score provides important objective data, it is intended for informational purposes only and does not constitute a recommendation. Medical management decisions should be made by a healthcare provider with an understanding of the full medical history and clinical assessment of the patient. For full test specifications and related publications, please visit VectraScore.com.

Laboratory Director: Bruce F Arnold, MD, FCAP
Crescendo Bioscience, Inc. a Myriad Genetics Company
 320 Wakara Way, Salt Lake City, UT 84108
VectraScore.com | F: 1-877-743-8640 | P: 1-877-743-8639

The Vectra test is intended for clinical use. Crescendo Bioscience Inc. and Myriad Genetics, Inc. developed Vectra and determined its performance characteristics. The Crescendo Bioscience Clinical Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing and is a College of American Pathologists Accredited Laboratory.

PATIENT: Jane Doe	DOB: NOV-1-1970	PATIENT ID: 000-000-0000	GENDER: Female
-------------------	-----------------	--------------------------	----------------

Individual Biomarker Results

TYPE	BIOMARKER	RESULT / UNITS	RA RANGE [†]	RA PERCENTILE [‡]
ACUTE PHASE PROTEINS	SAA	1.1 ug/mL	0.29 - 85	8%
	CRP	0.32 mg/L	0.19 - 92	64%
ADHESION MOLECULES	VCAM-1	0.41 ug/mL	0.39 - 1.2	68%
CYTOKINE-RELATED PROTEINS	IL-6	2.9 pg/mL	2.5 - 200	6%
	TNF-RI	1.2 ng/mL	0.8 - 3.9	2%
GROWTH FACTORS	EGF §	190 pg/mL	12 - 410	17%
	VEGF-A	330 pg/mL	75 - 790	26%
HORMONES	LEPTIN	10 ng/mL	1.5 - 120	18%
	RESISTIN	5.7 ng/mL	3.5 - 21	51%
MATRIX METALLOPROTEINASES	MMP-1	5.6 ng/mL	1.3 - 23	21%
	MMP-3	17 ng/mL	7.9 - 160	10%
SKELETAL-RELATED PROTEINS	YKL-40	45 ng/mL	22 - 540	3%

[†] These 95% reference ranges were established from 325,781 patient samples tested at Crescendo Bioscience Clinical Laboratory.

[§] Inversely correlated with disease activity.

[‡] Subject's biomarker level relative to levels in RA patient specimens from which the RA ranges were determined.

Please note: The individual biomarker results, which are expressed to two significant figures, are required inputs into the algorithm used to calculate the Vectra Score. Clinical interpretation of individual biomarker levels, which have different weights in the Vectra algorithm, has not been established.

Complete Vectra Score History

COLLECTION DATE	SCORE	NOTES
Feb. 10, 2017	56	Unadjusted*
Nov. 15, 2019	44	
Mar. 25, 2020	63	
Jul. 30, 2020	72	

*As of December 4, 2017 the Vectra Score is adjusted based on the age, gender and adiposity of the patient.

Comments

While the Vectra Score provides important objective data, it is intended for informational purposes only and does not constitute a recommendation. Medical management decisions should be made by a healthcare provider with an understanding of the full medical history and clinical assessment of the patient. For full test specifications and related publications, please visit VectraScore.com.

Laboratory Director: Bruce F Arnold, MD, FCAP
Crescendo Bioscience, Inc. a Myriad Genetics Company
 320 Wakara Way, Salt Lake City, UT 84108
VectraScore.com | F: 1-877-743-8640 | P: 1-877-743-8639

The Vectra test is intended for clinical use. Crescendo Bioscience Inc. and Myriad Genetics, Inc. developed Vectra and determined its performance characteristics. The Crescendo Bioscience Clinical Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing and is a College of American Pathologists Accredited Laboratory.